hepatitis C

BMY’s Hepatitis C Franchise May See a Drop in Revenues in 2016
BMY’s Hepatitis C Franchise May See a Drop in Revenues in 2016
Market Realist
Bristol-Myers Squibb
hepatitis C
Daklinza
Sunvepra
Flag link:
AbbVie Files for Approval of Hepatitis C Treatment in the US
AbbVie Files for Approval of Hepatitis C Treatment in the US
Yahoo/GuruFocus
AbbVie
hepatitis C
glecaprevir/pibrentasvir
Flag link:
Gilead’s Patent Loss to Merck Started With a Broken Friendship
Gilead’s Patent Loss to Merck Started With a Broken Friendship
Bloomberg
Gilead Sciences
Merck
patents
hepatitis C
Sovaldi
Harvoni
Flag link:
Merck Wins Record $2.5 Billion Patent Verdict Against Gilead
Merck Wins Record $2.5 Billion Patent Verdict Against Gilead
Bloomberg
Merck
patents
Gilead Sciences
hepatitis C
Harvoni
Sovaldi
Flag link:
Gilead Sciences Inc.'s Best Moves in 2016
Gilead Sciences Inc.'s Best Moves in 2016
Motley Fool
Gilead Sciences
NASH
hepatitis C
filgotinib
Galapagos
Flag link:
Gilead's HCV NDA Means Nothing
Gilead's HCV NDA Means Nothing
Seeking Alpha
Gilead Sciences
hepatitis C
SOF/VEL/VOX
Epclusa
AbbVie
Flag link:
Gilead Sciences Inc.'s Worst Moves in 2016
Gilead Sciences Inc.'s Worst Moves in 2016
Motley Fool
Gilead Sciences
dividends
hepatitis C
M&A
Flag link:
Gilead Sciences' HCV Fall Was Partially Offset by HIV Business
Gilead Sciences' HCV Fall Was Partially Offset by HIV Business
Market Realist
Gilead Sciences
hepatitis C
HIV
Flag link:
After The Deluge, Hep C Players Look For Opportunity
After The Deluge, Hep C Players Look For Opportunity
Seeking Alpha
hepatitis C
Gilead Sciences
AbbVie
Epclusa
glecaprevir/pibrentasvir
sofosbuvir/velpatasvir
Flag link:
AbbVie's pan-genotypic hep C prospect shines in trials, putting the heat on rival Gilead
AbbVie's pan-genotypic hep C prospect shines in trials, putting the heat on rival Gilead
Fierce Pharma
AbbVie
hepatitis C
Gilead Sciences
Epclusa
Flag link:
Gilead hepatitis C pill was biggest 2015 drug cost for Medicare, Medicaid
Gilead hepatitis C pill was biggest 2015 drug cost for Medicare, Medicaid
Stat/Pharmalot
Gilead Sciences
hepatitis C
Medicare
Medicaid
Harvoni
Flag link:
Merck Reports Triple-Combo Results
Merck Reports Triple-Combo Results
https://yhoo.it/2fT1k83
Merck
hepatitis C
Flag link:
AbbVie reports positive 8-week data in HCV
AbbVie reports positive 8-week data in HCV
BioPharma Dive
AbbVie
hepatitis C
glecaprevir/pibrentasvir
Flag link:
Gilead's Q3 Bombshell: No More Hepatitis C R&D
Gilead's Q3 Bombshell: No More Hepatitis C R&D
Motley Fool
Gilead Sciences
R&D
hepatitis C
Flag link:
Unfazed by FDA Warning, Gilead Sciences' Stock Could Be Turning a Corner
Unfazed by FDA Warning, Gilead Sciences' Stock Could Be Turning a Corner
Motley Fool
FDA
Gilead Sciences
hepatitis C
Harvoni
Sovaldi
Flag link:
Good and bad news for Gilead
Good and bad news for Gilead
BioPharma Dive
Gilead Sciences
selonsertib
HIV
hepatitis C
NASH
Flag link:
Gilead May Lose Sovaldi’s European Patent
Gilead May Lose Sovaldi’s European Patent
Investopedia
Gilead Sciences
Sovaldi
Europe
patents
hepatitis C
Flag link:
FDA Warning Adds to Gilead’s Drug Woes (GILD)
FDA Warning Adds to Gilead’s Drug Woes (GILD)
Investopedia
FDA
warnings
hepatitis C
Gilead Sciences
Flag link:
FDA Adds Boxed Warning to Hepatitis C Drugs, Warns of Hepatitis B Reactivation Risk
FDA Adds Boxed Warning to Hepatitis C Drugs, Warns of Hepatitis B Reactivation Risk
RAPS.org
FDA
warnings
hepatitis C
hepatitis B
Flag link:
AbbVie Receives FDA Ranking for Hepatitis C Therapy
AbbVie Receives FDA Ranking for Hepatitis C Therapy
Yahoo/GuruFocus
AbbVie
FDA
hepatitis C
glecaprevir/pibrentasvir
Flag link:

Pages